Takeda gives Affymax $10M milestone payment for anemia therapy

08/10/2011 | Forbes

Takeda Pharmaceutical paid a $10 million milestone fee to Affymax after the FDA accepted a marketing application for anemia drug candidate peginesatide. The companies aim to co-promote the drug to anemic patients with chronic renal failure.

View Full Article in:

Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice President - Government Products
Health Alliance Plan
Detroit, MI
Director, Compliance - Health Plan Privacy & Security
Kaiser Permanente
Oakland, CA
Chief Medical Officer
VANDERBILT HEALTH AFFILIATE NETWORK
Nashville, TN
Commercial Health Insurance Strategist__Job #52-14
American Academy of Family Physicians
Leawood, KS
Manager of Payer Relations
Pharmacy Quality Solutions, Inc.
Raleigh/Durham, NC